Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination
PCORnet, United States, January 2021–January 2022

On April 1, 2022, this report was posted online as an MMWR Early Release.
Jason P. Block, MD1; Tegan K. Boehmer, PhD2; Christopher B. Forrest, MD, PhD3; Thomas W. Carton, PhD4; Grace M. Lee, MD5; Umed A. Ajani, MBBS2; Dimitri A. Christakis, MD6; Lindsay G. Cowell, PhD7; Christine Draper1; Nidhi Ghildayal, PhD1; Aaron M. Harris, MD2; Michael D. Kappelman, MD8; Jean Y. Ko, PhD2; Kenneth H. Mayer, MD9; Kshema Nagavedu, MPH1; Matthew E. Oster, MD2,10; Anuradha Paranjape, MD11; Jon Puro, MPA12; Matthew D. Ritchey2; David K. Shay, MD2; Deepika Thacker, MD13; Adi V. Gundlapalli, MD, PhD2
Summary What is already known about this topic?
Studies have found an increased risk for cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination, but few have compared these risks.
What is added by this report? Data from 40 health care systems participating in a large network found that the risk for cardiac complications was significantly higher after SARS-CoV-2 infection than after mRNA COVID-19 vaccination for both males and females in all age groups.
What are the implications for public health practice? These findings support continued use of recommended mRNA COVID-19 vaccines among all eligible persons aged ≥5 years.
